Core Insights - WuXi AppTec has implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash dividends [1] - The company has distributed a total of RMB4.88 billion in cash dividends to investors this year, which includes annual, special, and interim dividends [2] - The total cash dividends, along with share repurchases and cancellations, amount to RMB6.88 billion, representing over 70% of the net profit attributable to the owners of the company in 2024 [2] Company Overview - WuXi AppTec is a global provider of R&D and manufacturing services for the pharmaceutical and life sciences industries, operating across Asia, Europe, and North America [4] - The company offers integrated, end-to-end services through its CRDMO (Contract Research, Development, and Manufacturing Organization) platform, collaborating with nearly 6,000 partners in over 30 countries [4]

Core Viewpoint - WuXi AppTec is actively enhancing shareholder value through A-share repurchase and H-share acquisition programs, aimed at attracting and retaining talent while maintaining company stability [1][2][3] A-Share Repurchase and Cancellation - The company repurchased and cancelled A-shares worth RMB1.0 billion to uphold its value and protect shareholder interests [2][3] - From April 18, 2025, to June 20, 2025, WuXi AppTec acquired 15,775,377 A-shares, approximately 0.55% of total issued share capital, at an average price of RMB63.39 per share [3] - The cancellation of all repurchased A-shares was completed on June 24, 2025 [3] H-Share Acquisition - WuXi AppTec instructed the Scheme Trustee to acquire HKD2.5 billion worth of H-shares to support the 2025 H Share Award and Trust Scheme [2][3] - A total of 34,092,975 H-shares were acquired, representing approximately 1.19% of total issued share capital, with no dilution to existing shareholders [3] - The H-share acquisition aims to attract and retain top talent, enhancing management capabilities and business resilience [3] H Share Award and Trust Scheme - Under the scheme, up to HKD1.5 billion worth of H-shares will be granted if the company's 2025 revenue reaches at least RMB42.0 billion [3] - An additional HKD1.0 billion worth of H-shares will be granted if the revenue reaches at least RMB43.0 billion, totaling HKD2.5 billion [3]